Médecine

Paramédical

Autres domaines


S'abonner

Wilms tumor screening in diffuse capillary malformation with overgrowth and macrocephaly–capillary malformation: A retrospective study - 27/12/17

Doi : 10.1016/j.jaad.2017.06.014 
Caitlin M. Peterman, BS a, b, c, Sophie Vadeboncoeur, MD b, c, d, John B. Mulliken, MD c, e, Steven J. Fishman, MD c, f, Marilyn G. Liang, MD b, c,
a Tufts University School of Medicine, Boston, Massachusetts 
b Department of Dermatology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 
c Vascular Anomalies Center, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 
e Department of Plastic and Oral Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 
f Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 
d Department of Medicine, Dermatology Division, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada 

Correspondence to: Marilyn G. Liang, MD, Department of Dermatology, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115.Department of DermatologyBoston Children's Hospital300 Longwood AveBostonMA02115

Abstract

Background

CLOVES (congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and skeletal anomalies) syndrome is associated with regional bony and/or soft tissue overgrowth, capillary malformation, and an increased risk for Wilms tumor.

Objective

To evaluate the frequency of Wilms tumor in patients with 2 similar conditions: diffuse capillary malformation with overgrowth (DCMO) and macrocephaly–capillary malformation (M-CM).

Methods

Culling our Vascular Anomalies Center database, we retrospectively reviewed patients in whom DCMO and M-CM had been diagnosed and who were evaluated between 1998 and 2016 for possible development of Wilms tumor. Patients younger than 8 years of age at their last visit and not seen in more than 2 years were contacted for follow-up.

Results

The study comprised 89 patients: 67 with DCMO, 17 with M-CM, and 5 with an indeterminate diagnosis. No case of Wilms tumor was found in these groups.

Limitations

Some patients were younger than 8 years of age at last follow-up visit and the sample size was small.

Conclusion

Patients with DCMO do not appear to be at increased risk for Wilms tumor. Screening is probably unnecessary in DCMO unless there is associated hemihypertrophy. Although there were no cases in our cohort, there are 2 reports of M-CM associated with Wilms tumor in the literature.

Le texte complet de cet article est disponible en PDF.

Key words : diffuse capillary malformation, macrocephaly–capillary malformation, overgrowth, Wilms tumor

Abbreviations used : BWS, CLOVES, CM, CVM, DCMO, KTS, M-CM, PROS, WT


Plan


 Ms Peterman and Dr Vadeboncoeur contributed equally to this work.
 Funding sources: None.
 Conflicts of interest: None declared.
 Preliminary data from this study were presented at the 42nd Annual Meeting of the Society of Pediatric Dermatology, Minneapolis, MN; July 16, 2016.
 Reprints not available from the authors.


© 2017  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 77 - N° 5

P. 874-878 - novembre 2017 Retour au numéro
Article précédent Article précédent
  • Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas
  • Andre Vadimovich Moyakine, Bjorn Herwegen, Catharina Joanna Maria van der Vleuten
| Article suivant Article suivant
  • Outpatient dermatology consultation impacts the diagnosis and management of pediatric oncology patients: A retrospective study
  • Hannah Song, Sarah N. Robinson, Jennifer T. Huang

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.